• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.

作者信息

Kalil Andre C, Stebbing Justin

机构信息

Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Department of Surgery and Cancer, Imperial College London, London, UK.

出版信息

Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.

DOI:10.1016/S2213-2600(21)00358-1
PMID:34480862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8409093/
Abstract
摘要

相似文献

1
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.巴瑞替尼：在一项安慰剂对照试验中首个降低新冠肺炎死亡率的免疫调节治疗药物。
Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.
2
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.巴瑞替尼联合标准治疗对接受有创机械通气或体外膜肺氧合治疗的 COVID-19 重症住院成年患者的疗效和安全性：一项探索性、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3.
3
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.巴瑞替尼在中重度 2019 冠状病毒病患者中的应用。
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
4
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性（COV-BARRIER）：一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
5
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.使用简单血液学参数评估 COVID-19 住院患者使用巴瑞替尼获益的风险概况：适应性 COVID-19 治疗试验-2 的事后分析。
Ann Intern Med. 2024 Mar;177(3):343-352. doi: 10.7326/M23-2593. Epub 2024 Feb 27.
6
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
7
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.在接受有创机械通气或体外膜肺氧合治疗的 COVID-19 患者中，加用巴瑞替尼联合常规治疗降低了全因死亡率。
Ann Intern Med. 2022 Jun;175(6):JC64. doi: 10.7326/J22-0033. Epub 2022 Jun 7.
8
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.对信件的回复：巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？约根森等人
Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210.
9
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
10
Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.住院的老年和非老年严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 患者接受巴瑞替尼治疗后的继发感染和长期结局：来自匈牙利国家中心的一项比较研究。
Geroscience. 2024 Jun;46(3):2863-2877. doi: 10.1007/s11357-024-01099-y. Epub 2024 Feb 17.

引用本文的文献

1
The future of pharmaceuticals: Artificial intelligence in drug discovery and development.制药的未来：药物研发中的人工智能
J Pharm Anal. 2025 Aug;15(8):101248. doi: 10.1016/j.jpha.2025.101248. Epub 2025 Feb 26.
2
Baricitinib statistically significantly reduced COVID-19-related mortality: a systematic review and meta-analysis of five phase III randomized, blinded and placebo-controlled clinical trials.巴瑞替尼在统计学上显著降低了与新冠肺炎相关的死亡率：一项对五项III期随机、双盲和安慰剂对照临床试验的系统评价和荟萃分析。
Biol Methods Protoc. 2024 Jan 23;9(1):bpae002. doi: 10.1093/biomethods/bpae002. eCollection 2024.
3

本文引用的文献

1
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性（COV-BARRIER）：一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
2
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
3
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.
巴瑞替尼治疗冠状病毒病2019与继发性感染减少相关。
Open Forum Infect Dis. 2023 Apr 19;10(5):ofad205. doi: 10.1093/ofid/ofad205. eCollection 2023 May.
4
Growth Arrest of Alveolar Cells in Response to Cytokines from Spike S1-Activated Macrophages: Role of IFN-γ.肺泡细胞对刺突S1激活的巨噬细胞分泌的细胞因子的生长停滞：γ干扰素的作用
Biomedicines. 2022 Dec 1;10(12):3085. doi: 10.3390/biomedicines10123085.
5
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.托珠单抗与巴瑞替尼治疗 COVID-19 住院患者的疗效比较：一项开放标签、随机对照临床试验。
Clin Microbiol Infect. 2023 Mar;29(3):372-378. doi: 10.1016/j.cmi.2022.10.015. Epub 2022 Oct 20.
6
The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro.JAK1/2抑制剂巴瑞替尼减轻体外刺突诱导的免疫细胞和内皮细胞炎症反应。
Biomedicines. 2022 Sep 19;10(9):2324. doi: 10.3390/biomedicines10092324.
7
Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?补体C5a抑制：机械通气的COVID-19患者的一种新的治疗形式？
Lancet Respir Med. 2022 Dec;10(12):1103-1104. doi: 10.1016/S2213-2600(22)00365-4. Epub 2022 Sep 12.
8
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.鉴定已灭活的 COVID-19 恢复期血浆的特性及在输注患者中的反应。
Transfusion. 2022 Oct;62(10):1997-2011. doi: 10.1111/trf.17083. Epub 2022 Sep 5.
9
Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.调节2019冠状病毒病的因素：基于不良结局途径框架的机制理解
J Clin Med. 2022 Jul 31;11(15):4464. doi: 10.3390/jcm11154464.
10
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.巴瑞替尼治疗新型冠状病毒肺炎的人工智能辅助识别及临床疗效
Vaccines (Basel). 2022 Jun 15;10(6):951. doi: 10.3390/vaccines10060951.
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
4
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
5
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
6
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
7
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.在大流行期间治疗新冠病毒病——超说明书用药、同情用药及随机临床试验
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.
8
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.巴瑞替尼治疗 2 年以上的活动性类风湿关节炎患者的安全性概况。
J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.
9
Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials.脓毒症的早期目标导向治疗：临床试验中生存结果不一致问题的新解决方案。
Crit Care Med. 2017 Apr;45(4):607-614. doi: 10.1097/CCM.0000000000002235.
10
Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis.因脓毒症和严重脓毒症住院的实体器官移植受者的住院死亡率。
Clin Infect Dis. 2016 Jul 15;63(2):186-94. doi: 10.1093/cid/ciw295. Epub 2016 May 23.